$Nurix Therapeutics (NRIX.US)$ Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia Nurix Therapeutics (NRIX) announced that its drug bexobrutideg (NX-5948) has received Orphan Drug Designation (ODD) from the FDA for treating Waldenström macroglobulinemia (WM). Bexobrutideg is an oral, brain-penetrant BTK degrader currently in Phase 1a/b clinical trials for relapsed/refractory B-cell malignancies. The ODD grants ...
$Nurix Therapeutics (NRIX.US)$Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia 5 MINUTES AGO, 7:00 AM EDT
$Nurix Therapeutics (NRIX.US)$But watching close ifn it’s FACTUAL? Dont see anything on Company website! but here is what i seen and wanted to share just in case its true????? (((((((. Nurix Therapeutics treatment of Waldenstrom macroglobulinemia gets orphan status Mar. 13, 2025, 05:25 PM Nurix Therapeutics (NRIX)’ treatment of Waldenstrom macroglobulinemia was granted FDA orphan designation, according to a post on the agency’s website.
Trytosaveabit
OPNoobInvestor
:
If true? There is a good chance yes! About 75%+ of new orphan drug designations run day of or within a few days of news coming out!
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Nurix Therapeutics Stock Forum
Revolutionary AI Platform Drives 4 Cancer Drug Innovations: Nurix AACR 2025 Spotlight
Breakthrough: Nurix's Novel Brain-Penetrant Cancer Drug Receives Key FDA Designation
Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia
Nurix Therapeutics (NRIX) announced that its drug bexobrutideg (NX-5948) has received Orphan Drug Designation (ODD) from the FDA for treating Waldenström macroglobulinemia (WM). Bexobrutideg is an oral, brain-penetrant BTK degrader currently in Phase 1a/b clinical trials for relapsed/refractory B-cell malignancies.
The ODD grants ...
5 MINUTES AGO, 7:00 AM EDT
(((((((. Nurix Therapeutics treatment of Waldenstrom macroglobulinemia gets orphan status
Mar. 13, 2025, 05:25 PM
Nurix Therapeutics (NRIX)’ treatment of Waldenstrom macroglobulinemia was granted FDA orphan designation, according to a post on the agency’s website.
as this guy 👇
No comment yet